Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMBZIVP)

Drug Name
Tubocurarine Drug Info
Synonyms
Amelizol; Delacurarine; Jexin; Tubadil; Tubaine; Tubarine; Tubocurarin; Tubocurarinum; Chlorure de tubocurarine; Cloruro de tubocurarina; Dextrotubocurarine chloride; Intocostrine T; Isoquinoline alkaloid; Tubocurarina cloruro; Tubocurarina cloruro [DCIT]; Tubocurarine chloride; Tubocurarine hydrochloride; Tubocurarini chloridum; Chlorure de tubocurarine [INN-French]; Cloruro de tubocurarina [INN-Spanish]; Curarin-haf; D-Paracurarine chloride; D-Tubocurarine; D-Tubocurarine chloride; D-Tubocurarine dichloride; D-Tubocurarine hydrochloride; Delacurarine (TN); Jex (TN); Metubine (TN); Tubaine (TN); Tubarine (TN); Tubocurarine chloride (INN); Tubocurarine chloride (TN); Tubocurarine chloride (anhydrous); Tubocurarini chloridum [INN-Latin]; Tubocurarinum (TN); D-(+)-Tubocurarine chloride; Tubocurarine, chloride, hydrochloride, (+)-(8CI); D-7',12'-Dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraranium chloride; Tubocuraranium, 7',12'-dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyl-, chloride, hydrochloride; (+)-Tubocurarine; (+)-Tubocurarine chloride; (+)-Tubocurarine chloride hydrochloride; 2,2',2'-trimethyl-6,6'-bis(methyloxy)tubocuraran-2,2'-diium-7',12'-diol dichloride; 7',12'-Dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraranium; 7',12'-dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraran-2'-ium
Therapeutic ClassNeuromuscular Nondepolarizing Agents
Cross-matching ID
PubChem CID
6000
ChEBI ID
CHEMBL339427
CAS Number
CAS 57-95-4
TTD Drug ID
D05HSC
VARIDT Drug ID
DR00536

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Mucin type O-glycan biosynthesis 1.68 3.78e-1 20/36 (55.56%) GALNT10;GALNT6;ST6GALNAC2;...
Cell cycle 1.64 2.91e-1 110/124 (88.71%) CDC20;CCNA2;SMAD4;...
Renin-angiotensin system 1.62 2.25e-1 20/23 (86.96%) ANPEP;AGT;CPA3;...
Basal transcription factors 1.54 3.84e-1 37/45 (82.22%) GTF2A2;CDK7;TBPL1;...
Oxidative phosphorylation 1.50 4.37e-1 93/133 (69.92%) ATP6V1D;COX7A1;ATP5PB;...
Staphylococcus aureus infection 1.49 3.92e-1 72/95 (75.79%) DEFB1;KRT23;KRT16;...
Oocyte meiosis 1.47 4.06e-1 90/129 (69.77%) CDC20;CALML3;RBX1;...
Proteasome 1.45 3.99e-1 44/46 (95.65%) PSMD6;PSMB3;PSMA2;...
Pyrimidine metabolism 1.43 4.23e-1 40/56 (71.43%) DPYD;UMPS;NT5E;...
Proximal tubule bicarbonate reclamation 1.41 4.57e-1 21/23 (91.3%) GLS;ATP1B1;AQP1;...
Pantothenate and CoA biosynthesis 1.36 5.89e-1 14/21 (66.67%) DPYD;AASDHPPT
DNA replication 1.35 5.71e-1 34/36 (94.44%) POLE2;MCM6;PCNA;...
Bacterial invasion of epithelial cells 1.34 5.60e-1 59/77 (76.62%) SRC;CLTB;ACTR3;...
Other types of O-glycan biosynthesis 1.32 5.94e-1 29/47 (61.7%) ST6GAL1;GALNT10;GALNT6;...
Renin secretion 1.32 5.81e-1 61/69 (88.41%) GUCY1A1;CLCA2;CLCA4;...
D-Glutamine and D-glutamate metabolism 1.31 5.75e-1 5/5 (100%) GLS;GLUD1;GLUD2
Parkinson disease 1.30 5.69e-1 176/249 (70.68%) CALML3;PSMD6;CASP3;...
Aminoacyl-tRNA biosynthesis 1.29 5.72e-1 15/66 (22.73%) IARS2;QRSL1;GATB;...
N-Glycan biosynthesis 1.29 5.63e-1 38/50 (76%) MGAT2;ST6GAL1;MAN2A1;...
Pancreatic secretion 1.23 7.83e-1 87/102 (85.29%) CPB1;CLCA2;CLCA4;...
Tight junction 1.23 7.48e-1 130/169 (76.92%) SRC;CD1E;CLDN10;...
Hematopoietic cell lineage 1.22 7.59e-1 90/99 (90.91%) ANPEP;ITGA4;CD1E;...
Ubiquitin mediated proteolysis 1.21 7.68e-1 87/140 (62.14%) CDC20;RHOBTB1;MAP3K1;...
mRNA surveillance pathway 1.19 8.00e-1 71/98 (72.45%) PPP2R3A;PCF11;GSPT2;...
Sulfur relay system 1.18 8.26e-1 5/8 (62.5%) TST;MPST;NFS1;...
Drug metabolism 1.17 8.20e-1 78/151 (51.66%) DPYD;CYP2E1;FMO1;...
Apoptosis 1.16 8.24e-1 126/168 (75%) CTSZ;TNFSF10;LMNB1;...
Nucleotide excision repair 1.15 8.60e-1 40/47 (85.11%) RBX1;POLE2;RAD23B;...
Thermogenesis 1.15 8.43e-1 173/232 (74.57%) ACSL4;COX7A1;ADCY7;...
Huntington disease 1.15 8.22e-1 233/306 (76.14%) PSMD6;CLTB;CASP3;...
Longevity regulating pathway -1.35 3.79e-1 90/151 (59.6%) CLPB;RPS6KB2;HDAC1;...
MicroRNAs in cancer -1.35 3.78e-1 146/310 (47.1%) ERBB3;PLAU;MAP2K1;...
Insulin signaling pathway -1.36 3.74e-1 121/137 (88.32%) PIK3R3;SHC3;PRKAA2;...
Glutamatergic synapse -1.37 3.63e-1 97/114 (85.09%) GRIK1;SHANK1;ITPR1;...
Pancreatic cancer -1.38 3.64e-1 75/76 (98.68%) RPS6KB2;MAP2K1;RAC3;...
Fructose and mannose metabolism -1.39 3.57e-1 30/33 (90.91%) MPI;TIGAR;KHK;...
Protein digestion and absorption -1.39 3.69e-1 78/103 (75.73%) SLC36A1;COL14A1;COL1A2;...
Galactose metabolism -1.39 3.75e-1 26/31 (83.87%) HK3;HK2;MGAM;...
Legionellosis -1.39 3.79e-1 51/57 (89.47%) CASP9;NFKB2;RAB1B;...
Choline metabolism in cancer -1.40 3.75e-1 84/98 (85.71%) RPS6KB2;PLA2G4C;MAP2K1;...
MAPK signaling pathway -1.41 3.61e-1 272/294 (92.52%) CACNA1F;MAPK13;CACNB1;...
Neurotrophin signaling pathway -1.41 3.76e-1 107/119 (89.92%) MAPK13;RPS6KA2;IRAK1;...
Lipid and atherosclerosis -1.42 3.83e-1 190/215 (88.37%) CASP9;MAP2K7;AGER;...
AGE-RAGE signaling pathway in diabetic complications -1.45 3.72e-1 97/100 (97%) MAPK11;PLCB2;PRKCZ;...
Ferroptosis -1.47 3.55e-1 36/41 (87.8%) GCLC;GPX4;SLC3A2;...
PI3K-Akt signaling pathway -1.48 3.47e-1 317/354 (89.55%) ANGPT1;AREG;FGF3;...
Insulin resistance -1.49 3.45e-1 96/108 (88.89%) PTPRF;PRKCZ;NFKB1;...
Glycine, serine and threonine metabolism -1.49 3.60e-1 31/40 (77.5%) PGAM1;PSPH;AOC2;...
Transcriptional misregulation in cancer -1.52 3.21e-1 158/192 (82.29%) MYCN;BCL2A1;PLAU;...
Glycerolipid metabolism -1.52 3.46e-1 44/61 (72.13%) LPIN2;AKR1B10;PNPLA2;...
Other glycan degradation -1.55 3.01e-1 13/18 (72.22%) NEU2;FUCA1;MAN2C1;...
Focal adhesion -1.59 2.47e-1 180/201 (89.55%) PIP5K1C;ROCK2;COL6A3;...
Amino sugar and nucleotide sugar metabolism -1.61 2.40e-1 38/48 (79.17%) PMM2;HK3;HK2;...
HIF-1 signaling pathway -1.66 1.68e-1 105/109 (96.33%) ALDOC;ANGPT1;CAMK2B;...
Pentose phosphate pathway -1.69 1.59e-1 25/30 (83.33%) FBP1;PRPS1L1;PGLS;...
Protein processing in endoplasmic reticulum -1.71 1.52e-1 127/171 (74.27%) HSP90AB1;ERP29;DNAJC10;...
Type II diabetes mellitus -1.76 1.01e-1 42/46 (91.3%) PRKCZ;MAPK3;HK3;...
ECM-receptor interaction -1.79 9.45e-2 80/88 (90.91%) GP1BA;COL6A2;GP9;...
Rheumatoid arthritis -1.81 1.19e-1 78/93 (83.87%) IL23A;HLA-DMB;CTSL;...
Mineral absorption -1.85 1.34e-1 48/60 (80%) MT1M;FTH1;MT2A;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 2.5uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 6.66uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H